himss-2022-logo.pngJoin us in Booth #4000 at the 2022 HIMSS Global Health Conference & Exhibition

From the world leader in artificial intelligence for breast imaging, discover the ProFound impact iCAD’s award-winning portfolio of cancer detection, density assessment, and risk evaluation solutions can have on your reading workflow and interoperability requirements at HIMSS from March 14-18 in Booth #4000.

Additionally, join a showcase session on March 15th at Booth #2121, where we will discuss best practices for integrating AI into your IT environment along with VMware® and NVIDIA®.

  • With about 2X improved clinical performance compared to the leading competitors1, ProFound AI® is unrivaled in improving reading accuracy2 and decreasing reading time to help detect cancer earlier
  • The only deep-learning density assessment software compatible with multiple vendors3, PowerLook® Density Assessment simplifies and standardizes breast density reporting and stratification with ease
  • Now available for 2D and 3D mammography, ProFound AI® Risk is the world’s first clinical decision support tool that provides an accurate4 short-term breast cancer risk estimation based only on a mammogram

Schedule a Meeting

Laurence Yudkovitch

Technical Product Manager, AI at iCAD, Inc.

Laurence Yudkovitch.png

Josh Dagenhart.png

Josh Dagenhart

AI Solutions Architect Manager at iCAD, Inc.

Ready to get started? Sign up now!

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat." - Lorem ipsum

“As technology is advancing and becoming a more integral part of our day-to-day workflow, partnering with organizations that provide a clear advantage in AI technologies, like iCAD, has been a critical focus for our facility in recent years. We have done a thorough evaluation of all of the other available AI technologies for breast imaging, but ultimately we found ProFound AI to be the best solution. With its multi-vendor flexibility, ProFound AI seamlessly integrated into our system and clinical workflow.”

– Matt Dewey, Chief Information Officer, Wake Radiology

Learn how iCAD's flexible deployment options empower you to maximize your investment in NVIDIA GPUs and VMware’s virtual environment during a presentation on March 15th at 11am EST in Booth #2121.


Laurence Yudkovitch.png
Laurence Yudkovitch 
Technical Product Manager, AI at iCAD, Inc.

Josh Dagenhart.png
Josh Dagenhart
AI Solutions Architect Manager at iCAD, Inc.

VMware HIMSS Demo and Theater iCAD session is March 15th at 11am EST. Booth # 2121.


Unrivaled by any other AI solution available today, ProFound AI improves radiologists’ sensitivity by 8 percent, and reduces false positives and unnecessary patient recall rates by 7.2 percent.

The latest version offers up to a 10% incremental improvement in specificity performance while maintaining an industry-leading high sensitivity level.


ProFound AI delivers unmatched, clinically proven time-savings benefits to radiologists, slashing reading time by 52.7%.

Further, Certainty of Finding and Case Scores assist in prioritizing caseload and clinical decision-making, reducing physician burnout.


With thousands of installations worldwide, ProFound AI offers multi-vendor compatibility and seamlessly integrates into the diagnostic process.

Now compatible with Hologic Clarity HD®!


Today’s unprecedented screening challenges call for unparalleled AI solutions, streamlining workflow and elevating outcomes.

ProFound AI flexibly integrates with major PACS, offering an intuitive, system-wide solution for improved workflow and decision support in any reading environment.


With market-leading agility, ProFound AI offers a practical enterprise-wide solution with powerful results.

With access to our complete portfolio of cancer detection, density assessment and risk evaluation solutions on one centralized server, streamlined deployment of state-of-the-art breast imaging technology at scale is simple.


Now available for 2D and 3D mammography, ProFound AI® Risk is the world’s first clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman.

Specifically designed to factor in racial and ethnic backgrounds, ProFound AI Risk offers an inclusive, first-in-kind approach to precision screening.

Consectetur adipiscing elit...

Joanna C.

"Et harum quidem rerum facilis est et expedita distinctio!"

Stanley T.

"Nam libero tempore, cum soluta nobis est eligendi."

Danielle W.

"Temporibus autem quibusdam et aut officiis debitis!"

1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Accessed 1-19-22. FDA 510K submissions K182373, K201019, K193229.
2. Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
3. Based on publicly available data as of September 2021. For GE and Hologic only. Uses 2D synthesized images.
4. iCAD data on file.